N-glycomic profiling of colorectal cancer according to tumor stage and location
»
N-glycomic profiling of colorectal cancer according to tumor stage and location
Changes in the glycosylation seen in various types of cancer, including colorectal cancer (CRC). Glycans, the sugar moieties of glycoconjugates, is involved in many important functions relevant to cancer and can be of value as a biomarker.
In this study, we have used mass spectrometry to analyze the N-glycan profile of 35 CRC tissue samples and 10 samples of healthy tissue from patients with non-CRC undergoing surgery for other reasons. Tumor samples were divided into groups depending on the location of the tumor (intestinal right or left) and phase (II or III), while samples of healthy intestine is divided into the right or left.
The level of N-glycan composition and class of neutral and acidic glycans are analyzed in a total of ten different groups. Surprisingly, no significant difference in the level of glycan when all right-and left-sided CRC samples are compared, and some differences (such as the H3N5 abundance neutral N-glycan) visible when the sample is divided by both location and stage. Some significant differences were found in the levels of glycans and glycan class when the phase II and III samples were compared, and these glycans can be of value as a potential new marker of cancer progression.
In order to validate our findings, we analyzed samples of healthy tissue of the colon right and left and did not find a significant difference in the level of one of the glycans are analyzed, confirming that our findings when comparing samples of CRC from the right and left colon was not due to normal variation glycans level between right and left intestines healthy. In addition, the levels of glycans H4N3F1P1 acid, H5N4F1P1, and S1H5N4F1 found changes in certain cancers but gut the location-specific manner, suggesting that the CRC affects the level of glycan in the same way regardless of the location of the tumor.
N-glycomic profiling of colorectal cancer according to tumor stage and location
Sialylation and bioactivity Protein Reduces Serum Amyloid P antifibrotic in Sera of Patients with Idiopathic Pulmonary Fibrosis
Pulmonary fibrosis is a chronic and usually fatal disorder characterized by the progressive formation of scar tissue such as in the lungs. silicic acid is often found as a terminal sugar on glycoconjugates such extracellular protein glycosylations. Sialidases, also known as neuraminidases, glycoconjugates desialylate. Serum amyloid P (SAP), a serum pentameric glycoprotein which has two sialic acids in each polypeptide, inhibits the differentiation of monocytes into fibrocytes and promote human PBMC to accumulate high levels of extracellular IL-10.
When SAP desialylated with sialidase, the effect of SAP on fibrocyte differentiation and IL-10 were severely hampered accumulation. Interestingly, in patients with pulmonary fibrosis, no increased level of sialidase activity in bronchoalveolar lavage fluid, increased levels of sialidases in the lungs, and decreased levels of SAP in the sera. To elucidate the role of SAP desialylation in pulmonary fibrosis (IPF) the pathogenesis of idiopathic, we purified serum SAP from IPF patients and healthy controls and gauge the extent of sialylation and bioactivity of purified SAP.
Ibrutinib drug-Bovine Serum Albumin (BSA) Conjugate
Description: Untagged synthetic panspecies Galactose BSA Glycoconjugate for WB, ELISA. The biological activity of this protein has not yet been tested.
Glycated Bovine Serum Albumin (BSA) with ?-Galactose
Description: Untagged synthetic panspecies Galactose BSA Glycoconjugate for WB, ELISA. The biological activity of this protein has not yet been tested.
Glycated Bovine Serum Albumin (BSA) with ?-Galactose
Description: Untagged synthetic panspecies Galactose BSA Glycoconjugate for WB, ELISA. The biological activity of this protein has not yet been tested.
(DRAAGQPAG)3 peptide (repeat-sequence peptide of the P. vivax circumsporozoite protein, CSP) conjugated with BSA
Description: A competitive inhibition quantitative ELISA assay kit for detection of Bovine Serum Albumin (BSA) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Description: A competitive inhibition quantitative ELISA assay kit for detection of Bovine Serum Albumin (BSA) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.
Bovine serum albumin (BSA) removal kit (Antibody based aff matrix; sufficient to remove 1-2 mg BSA from Bioprocessed material), 2 ml aff column
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 20-40 mg BSA from Bioprocessed material), 2 ml aff column
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 50-100 mg BSA from Bioprocessed material), 5 ml aff column
Albumin (Human, Mouse, rat, bovine and others) removal kit (synthetic dye based matrix; sufficient to remove 250-500 mg BSA from Bioprocessed material), 25 ml aff column
Description: Galactose Mutarotase (GALM) is a cytoplasmic enzyme that belongs to the Aldose Epimerase family. GALM is a Mutarotase that converts alpha-Aldose to the beta -Anomer. GALM is active on D-Glucose, L-Arabinose, D-Xylose, D-Galactose, Maltose and Lactose. GALM may be required for normal Galactose metabolism by maintaining the equilibrium of alpha- and beta - anomers of Galactose.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
Description: A high purity chemical with various applications in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.
We found that some IPF patients have abnormally high levels of NEU3 sialidase in their sera and that the SAP in the sera of patients with IPF have abnormally high levels of abnormally low desialylation and the ability to inhibit fibrocyte differentiation and induces accumulation of extracellular IL-10 by PBMCs. These results indicate that SAP desialylation may play a role in the pathogenesis of IPF and which inhibits NEU3 could be a potential therapeutic target for IPF.
